Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.

Attard G, Reid AH, Olmos D, de Bono JS.

Cancer Res. 2009 Jun 15;69(12):4937-40. doi: 10.1158/0008-5472.CAN-08-4531. Epub 2009 Jun 9. Review.

2.

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LW, de Bono JS.

Cancer Res. 2009 Apr 1;69(7):2912-8. doi: 10.1158/0008-5472.CAN-08-3667.

3.

Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.

Harris WP, Mostaghel EA, Nelson PS, Montgomery B.

Nat Clin Pract Urol. 2009 Feb;6(2):76-85. doi: 10.1038/ncpuro1296. Review. Erratum in: Nat Clin Pract Urol. 2009 Mar;6(3):173.

4.

Anti-NF-kappaB and anti-inflammatory activities of synthetic isothiocyanates: effect of chemical structures and cellular signaling.

Prawan A, Saw CL, Khor TO, Keum YS, Yu S, Hu L, Kong AN.

Chem Biol Interact. 2009 May 15;179(2-3):202-11. doi: 10.1016/j.cbi.2008.12.014. Epub 2008 Dec 30.

5.

Fetal mouse Cyp1b1 and transplacental carcinogenesis from maternal exposure to dibenzo(a,l)pyrene.

Castro DJ, Baird WM, Pereira CB, Giovanini J, Löhr CV, Fischer KA, Yu Z, Gonzalez FJ, Krueger SK, Williams DE.

Cancer Prev Res (Phila). 2008 Jul;1(2):128-34. doi: 10.1158/1940-6207.CAPR-07-0004. Epub 2008 Mar 19.

6.

Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer.

Lu H, Chen CS, Waxman DJ.

Cancer Gene Ther. 2009 May;16(5):393-404. doi: 10.1038/cgt.2008.93. Epub 2008 Nov 14.

7.

17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response.

Bruno RD, Gover TD, Burger AM, Brodie AM, Njar VC.

Mol Cancer Ther. 2008 Sep;7(9):2828-36. doi: 10.1158/1535-7163.MCT-08-0336.

8.

Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions.

Doloff JC, Waxman DJ, Jounaidi Y.

Hum Gene Ther. 2008 Dec;19(12):1383-400. doi: 10.1089/hum.2008.056.

9.

Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.

Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK, Guo Z, Fang HB, Njar VC, Brodie AM.

Mol Cancer Ther. 2008 Aug;7(8):2348-57. doi: 10.1158/1535-7163.MCT-08-0230.

10.

CYP17 inhibitors for prostate cancer treatment--an update.

Moreira VM, Salvador JA, Vasaitis TS, Njar VC.

Curr Med Chem. 2008;15(9):868-99. Review.

PMID:
18473796
11.

Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.

Ma J, Waxman DJ.

Mol Cancer Ther. 2008 Jan;7(1):79-89. doi: 10.1158/1535-7163.MCT-07-0584.

12.

Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model.

Chen CS, Jounaidi Y, Su T, Waxman DJ.

Cancer Gene Ther. 2007 Dec;14(12):935-44. Epub 2007 Sep 14.

13.

Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.

Bruno RD, Njar VC.

Bioorg Med Chem. 2007 Aug 1;15(15):5047-60. Epub 2007 May 23. Review.

14.

Ins and outs of dietary phytochemicals in cancer chemoprevention.

Russo GL.

Biochem Pharmacol. 2007 Aug 15;74(4):533-44. Epub 2007 Feb 28. Review.

PMID:
17382300
15.

Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis.

Khor TO, Huang MT, Kwon KH, Chan JY, Reddy BS, Kong AN.

Cancer Res. 2006 Dec 15;66(24):11580-4.

16.
17.

The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis.

Nebert DW, Dalton TP.

Nat Rev Cancer. 2006 Dec;6(12):947-60. Review.

PMID:
17128211
18.

Indole-3-carbinol in the maternal diet provides chemoprotection for the fetus against transplacental carcinogenesis by the polycyclic aromatic hydrocarbon dibenzo[a,l]pyrene.

Yu Z, Mahadevan B, Löhr CV, Fischer KA, Louderback MA, Krueger SK, Pereira CB, Albershardt DJ, Baird WM, Bailey GS, Williams DE.

Carcinogenesis. 2006 Oct;27(10):2116-23. Epub 2006 May 16.

PMID:
16704990
19.

In utero exposure of mice to dibenzo[a,l]pyrene produces lymphoma in the offspring: role of the aryl hydrocarbon receptor.

Yu Z, Loehr CV, Fischer KA, Louderback MA, Krueger SK, Dashwood RH, Kerkvliet NI, Pereira CB, Jennings-Gee JE, Dance ST, Miller MS, Bailey GS, Williams DE.

Cancer Res. 2006 Jan 15;66(2):755-62.

20.

Overview of mechanisms of cancer chemopreventive agents.

De Flora S, Ferguson LR.

Mutat Res. 2005 Dec 11;591(1-2):8-15. Epub 2005 Aug 16. Review.

PMID:
16107270

Supplemental Content

Support Center